Verily Health Secures New Investment from NVIDIA to Advance Precision Health AI Platform

The new investment aimed at scaling adoption of the Verily Pre Platform and supporting the growth of Verily Me platform

Verily Health, a medical data and healthcare technology company, has secured a strategic investment from NVIDIA to support the development and commercial deployment of its precision health artificial intelligence platform, as per the company’s recent announcement.

The latest capital also included additional investment from existing investor CU Healthcare Innovation Fund II, LP. Verily's current investors also include Alphabet, Series X Capital, UCHealth, and others.

The new investment aimed at scaling adoption of the Verily Pre Platform, the company's flagship data and AI platform, which helps healthcare organizations make their data AI-ready and deploy AI responsibly across research and care. The platform serves as the central data and technical foundation across research and health system operations.

The investment is also intended to support the growth of Verily Me, the company's patient engagement offering, extending Verily's capabilities to support individuals throughout their healthcare journey.

The development follows a collaboration announced in October 2025, under which NVIDIA’s software and accelerated computing capabilities were integrated into Verily’s Pre platform.

The integration includes NVIDIA NeMo, NVIDIA Parabricks, RAPIDS, and NVIDIA CUDA-X Data Science within Verily Workbench, along with access to NVIDIA Blackwell and NVIDIA B200GPU infrastructure.

Through the integration, researchers using Verily Pre Workbench can work with multimodal biomedical datasets from NVIDIA AI libraries and leverage computing capabilities for data science, generative AI, and genomic analysis to support faster computational efficiency and speed.

Additionally, it seeks to advance Multimodal Foundation Models that leverage NVIDIA-accelerated infrastructure to scale Forecast 1.0, Verily’s proprietary foundation model.

It integrates genomic sequencing data directly with longitudinal EHR flowsheets to predict long-term chronic disease risk trajectories and organ decompensation.

Commenting on the new investment, Stephen Gillett, Chairman and CEO of Verily. “We are pleased to welcome NVIDIA as a new investor in Verily. These investments strengthen our ability to pursue the opportunity ahead. Together, these investments and the continued support of our current investors accelerate our vision to build a trusted foundation for healthcare, bringing together the information and intelligence needed to power better decisions and unlock the full potential of AI across the healthcare ecosystem”.

Stay tuned for more such updates on Digital Health News